Matches in Wikidata for { <http://www.wikidata.org/entity/Q66084052> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q66084052 description "clinical trial" @default.
- Q66084052 description "ensayu clínicu" @default.
- Q66084052 description "klinisch onderzoek" @default.
- Q66084052 description "клінічне випробування" @default.
- Q66084052 name "Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis" @default.
- Q66084052 name "Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis" @default.
- Q66084052 type Item @default.
- Q66084052 label "Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis" @default.
- Q66084052 label "Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis" @default.
- Q66084052 prefLabel "Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis" @default.
- Q66084052 prefLabel "Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis" @default.
- Q66084052 P1050 Q66084052-83BE87E2-2C3E-4DBE-B982-8D4A3D65B1C6 @default.
- Q66084052 P1132 Q66084052-75A1016B-9B62-4A33-BB05-859A701335D0 @default.
- Q66084052 P1476 Q66084052-5EC43EB8-3B0E-4267-8FB8-1BF4FF42AC14 @default.
- Q66084052 P17 Q66084052-199429F2-9CE7-4E35-B134-5B6BF79FFB5E @default.
- Q66084052 P17 Q66084052-33996063-BD52-4EF3-82B3-352406456AFB @default.
- Q66084052 P17 Q66084052-5B332CBC-90AC-4A19-9F3B-6AF558FDBE2A @default.
- Q66084052 P17 Q66084052-66BB5B6D-34D4-449F-8DFB-8FC05E51F227 @default.
- Q66084052 P17 Q66084052-826D767B-A07F-4B2F-A915-0B85701A40D5 @default.
- Q66084052 P17 Q66084052-912713A3-649B-4FCB-B0E0-B32C67550679 @default.
- Q66084052 P17 Q66084052-97A3F7C2-5341-4D87-AF09-CB7ED70FB6A0 @default.
- Q66084052 P1813 Q66084052-9C601E09-B4D4-4216-98FC-FEB57E61BC37 @default.
- Q66084052 P2899 Q66084052-02A959DA-43CF-42FE-9EDB-5D2DFA9D2ADF @default.
- Q66084052 P3098 Q66084052-3FCBF91A-5B37-43E4-8D9D-31F6DA9BC84F @default.
- Q66084052 P31 Q66084052-5C190F4F-5C7E-419E-9B04-C2CC64E35FA7 @default.
- Q66084052 P4135 Q66084052-92F19869-FA31-43CD-8809-08D474DB308D @default.
- Q66084052 P580 Q66084052-F1ABCB51-CEE2-4009-820A-7E378F4AA4DE @default.
- Q66084052 P582 Q66084052-4FCEE4DC-E187-4A5F-A047-EAE020965D39 @default.
- Q66084052 P6099 Q66084052-B56C15BD-C8E1-4695-AC0A-51BDDB4B4378 @default.
- Q66084052 P8363 Q66084052-97308F25-94AC-4BA4-ADB0-B7B0E2F9C98E @default.
- Q66084052 P1050 Q2453464 @default.
- Q66084052 P1132 "+77" @default.
- Q66084052 P1476 "A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Symptomatic Ulcerative Colitis Patients With Moderate to Severe Disease Activity" @default.
- Q66084052 P17 Q145 @default.
- Q66084052 P17 Q211 @default.
- Q66084052 P17 Q212 @default.
- Q66084052 P17 Q219 @default.
- Q66084052 P17 Q28 @default.
- Q66084052 P17 Q36 @default.
- Q66084052 P17 Q37 @default.
- Q66084052 P1813 "TOP2" @default.
- Q66084052 P2899 "+18" @default.
- Q66084052 P3098 "NCT02888379" @default.
- Q66084052 P31 Q30612 @default.
- Q66084052 P4135 "+75" @default.
- Q66084052 P580 "2016-09-01T00:00:00Z" @default.
- Q66084052 P582 "2017-06-28T00:00:00Z" @default.
- Q66084052 P6099 Q42824440 @default.
- Q66084052 P8363 Q78089383 @default.